Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may offer a new way to measure smell recovery

NCT ID NCT07819162

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether functional MRI can detect changes in the brain's smell-processing regions after people with severe chronic rhinosinusitis with nasal polyps receive monoclonal antibody treatment. The study enrolls 40 adults with smell loss who are eligible for biologic therapy. Participants undergo fMRI while identifying odors, and researchers compare brain activity patterns with standard smell tests to see if the imaging measure tracks with real-world smell improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
monoclonal antibody biologics for severe chronic rhinosinusitis with nasal polyps
What this could lead to
If the brain-imaging measure tracks with real smell improvement, it could give doctors a new way to measure whether biologic treatment is helping the sense of smell.
What could go wrong
The trial is small, with 40 participants, and the fMRI measure is experimental. Brain activity patterns may not match up with how well people actually smell, and results in this group may not apply to others with smell loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2027

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A study population of patients form the out-patient clinic at Copenhagen University Hospital, Rigshospitalet with CRSwNP offered treatment with biologics meeting the criteria for treatment with biologic as stated in the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS 2020) as well as the Danish Medicines Council criteria to be considered for inclusion. Furthermore, healthy controls matched by sex and age recruited through advertisement.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or above * Olfactory dysfunction (i.e., a TDI score \< 30.75) * Eligible for treatment with biologics (i.e., meeting the Danish criteria for treatment with biologics (40) which includes fulfillment of the EPOS criteria for CRS. * Either treatment naïve to biologics or had their first injection within a maximum of 48 hours prior to the scan. * No other obvious explanation for the olfactory dysfunction (including, but not limited to: head trauma, sinus surgery, tumors in the nose or brain, upper respiratory infection, neurological or psychiatric disease) * Control group: normosmic at baseline (i.e., TDI-score \>30.75) Exclusion Criteria: * Previously recognized loss of sense of smell and taste due to other sinonasal or neurological conditions. * Neurodegenerative disorders known to cause olfactory deficits (Parkinson's, Alzheimer's, Lewy-Body Dementia, Amyotrophic lateral Sclerosis etc.) * Other obvious explanation for the OD (i.e., smell loss occurring in relation to one of the following (including, but not limited to): head trauma, sinus surgery, upper respiratory infection. * Contraindications for MRI scan including: * Implants or prostheses of magnetic metal * Metal foreign bodies * Pregnancy * Severe claustrophobia * Unable to complete the full MRI session. * Not able to comprehend written and/or spoken Danish language.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis with nasal polyps (CRSWNP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis with nasal polyps (CRSWNP) Functional magnetic resonance imaging (FMRI) Olfactory dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen University Hospital, Rigshospitalet

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.